heart failure Archives -

A study of a mobile health app used to support patients hospitalised with heart failure has concluded that

Digital health app linked to better outcomes in heart failure

https://pharmaphorum.com/news/digital-health-app-linked-to-better-outcomes-in-heart-failure/

News/ News/ R&D

AZ bites back at rivals with new Farxiga data in heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, cardiovascular disease, Eli Lilly, Farxiga, heart failure 0 Comment

AstraZeneca’s SGLT2 inhibitor Farxiga has hit the mark in a phase 3 heart failure trial that brings it

AZ bites back at rivals with new Farxiga data in heart failure

https://pharmaphorum.com/news/az-bites-back-at-rivals-with-new-farxiga-data-in-heart-failure/

Digital/ News/ News/ News/ Patients

Digital interventions cut heart failure mortality, study shows

Phil Taylor digital, digital health, heart failure, rehabilitation 0 Comment

An analysis of 10 clinical trials of digital health interventions targeted at patients recently hospitalised for acute heart

Digital interventions cut heart failure mortality, study shows

https://pharmaphorum.com/news/digital-interventions-cut-heart-failure-mortality-study/

News/ News/ R&D

Merck turns to cardiovascular pipeline for its post-Keytruda future

Phil Taylor atherosclerosis, cardiovascular disease, heart failure, Merck & Co, pulmonary arterial hypertension, R&D 0 Comment

For some years industry observers have been asking what Merck & Co can do to reduce its reliance

Merck turns to cardiovascular pipeline for its post-Keytruda future

https://pharmaphorum.com/news/merck-turns-to-cardiovascular-pipeline-for-its-post-keytruda-future/

News/ News/ R&D

Cytokinetics’ heart drug omecamtiv strikes out in heart failure trial

Phil Taylor Bristol-Myers Squibb, cardiovascular disease, Cytokinetics, heart failure, mavacamten, omecamtiv mecarbil 0 Comment

Cytokinetics’ hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to

Cytokinetics’ heart drug omecamtiv strikes out in heart failure trial

https://pharmaphorum.com/news/cytokinetics-heart-drug-omecamtiv-strikes-out-in-heart-failure-trial/

Market Access/ News/ News

Jardiance pulls ahead of Forxiga with heart failure approval in EU

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Entresto, heart failure, Jardiance, Novartis 0 Comment

Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor Jardiance has become the first drug in the class to be

Jardiance pulls ahead of Forxiga with heart failure approval in EU

https://pharmaphorum.com/news/jardiance-pulls-ahead-of-forxiga-in-european-heart-failure-market/

News/ News/ R&D

Stage set for Jardiance to become universal heart failure drug

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Farxiga, heart failure, Jardiance 0 Comment

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting

Stage set for Jardiance to become universal heart failure drug

https://pharmaphorum.com/news/stage-set-for-jardiance-to-become-universal-heart-failure-drug/

Market Access/ News/ News

FDA expands use of Abbott’s heart sensor with new approval

Phil Taylor Abbott, biosensors, digital, heart failure, medical device, regulatory approval 0 Comment

The FDA has approved expanded labelling for Abbott’s CardioMEMS HF System, an implantable sensor that provides an early

FDA expands use of Abbott’s heart sensor with new approval

https://pharmaphorum.com/news/fda-expands-use-of-abbotts-heart-sensor-with-new-approval/

News/ News/ R&D

AZ, Moderna say mRNA drug is promising in heart failure

Phil Taylor AstraZeneca, cardiovascular, heart failure, Moderna, mRNA 0 Comment

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of

AZ, Moderna say mRNA drug is promising in heart failure

https://pharmaphorum.com/news/az-moderna-say-mrna-drug-is-promising-in-heart-failure/

Trending

heart failure

Login